<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02415478</url>
  </required_header>
  <id_info>
    <org_study_id>14-002</org_study_id>
    <nct_id>NCT02415478</nct_id>
  </id_info>
  <brief_title>Bronchioscopic Lung Volume Reduction (BLVR)</brief_title>
  <acronym>BLVR</acronym>
  <official_title>The Effect of Endoscopic Lung Volume Reduction Via Endobronchial Valves on Breath Muscle Power by Patients With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RWTH Aachen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For patients with emphysema, lung volume reduction by insertion of endobronchial valves could&#xD;
      be an expedient approach to improve the diaphragm function and the strength of breathing&#xD;
      muscles. Therefore in the present study investigators intend to examine, whether the lung&#xD;
      volume reduction by valves might improve the physical capacity and the quality of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In line with routine explorations it is necessary to clarify whether a patient is suitable&#xD;
      for the lung volume reduction by insertion of endobronchial valves. To address this question&#xD;
      lung function diagnostics, 6-minutes-walk-test, blood withdrawal, CT of the thorax, lung&#xD;
      perfusion scintigraphy and transthoracic echocardiography have to be performed.&#xD;
&#xD;
      After confirmation of the suitability for the endoscopic lung volume reduction patients who&#xD;
      fulfill all other eligibility criteria will be educated about the aim and performance of the&#xD;
      study by an investigator.&#xD;
&#xD;
      Following examination will be performed additional due to the study: determination of the&#xD;
      strength of breathing muscles via sniff nasal pressure (PImax, PE max, P0.1), determination&#xD;
      of the life quality index via St.-George-questionary and determination of the depression&#xD;
      score via the Short Form 8 (SF-8) Health Survey.&#xD;
&#xD;
      After that endobronchial valve will be implanted and a permanent post-operative examination&#xD;
      will be performed for 24 hours.&#xD;
&#xD;
      Three, respectively nine month after the implanting follow up exploration will be performed&#xD;
      on the study patients. Once again the determination of the strength of breathing muscles, the&#xD;
      life quality index via St.-George-questionary and the depression score via SF-8 will be&#xD;
      performed to clarify an improvement of the physical capacity and the quality of life&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Breath Muscle Power</measure>
    <time_frame>Change of breathing strength 3 (respectively 9) months after the bronchoscopy</time_frame>
    <description>Maximal Inspiratory Pressure (PImax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Breath Muscle Power</measure>
    <time_frame>Change of breathing strength 3 (respectively 9) months after the bronchoscopy</time_frame>
    <description>Maximal Expiratory Pressure (PEmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Breath Muscle Power</measure>
    <time_frame>Change of breathing strength 3 (respectively 9) months after the bronchoscopy</time_frame>
    <description>Neuromuscular drive (P0.1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Breath Muscle Power</measure>
    <time_frame>Change of breathing strength 3 (respectively 9) months after the bronchoscopy</time_frame>
    <description>Sniff nasal pressure</description>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>endoscopic lung volume reduction by valves</intervention_name>
    <description>Independent of the study, subject will get a bronchoscopy with chartis measurement in general anaesthesia. chartis measurement is a Balloon angioplasty. Balloon will be well-positioned in lung and filled by air for occlusion of lobe of the lung. System recognizes collateral ventilation of lobe of the lung via calculation of airflow resistance.&#xD;
Negative result allows the endoscopic placement of selfexpandig endobronchial valves in the subject lung. Inhale airflow will be inhibit an enclosed air and liquids can exhaust.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with severe COPD (GOLD stage III or IV)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  bilateral lung emphysema after CT&#xD;
&#xD;
          -  previous guidelines-based therapy of COPD (including vaccinations against Pneumococcal&#xD;
             infections and seasonal influenza)&#xD;
&#xD;
          -  nicotine abstention for not less than three months, documented by CO-HB (haemoglobin)&#xD;
             &lt; 2%&#xD;
&#xD;
          -  FEV 1 (Forced Expiratory Volume 1 / one second capacity) ≤ 45% of reference value,&#xD;
             after bronchodilatation&#xD;
&#xD;
          -  total lung capacity (TLC) ≥ 100% of reference value&#xD;
&#xD;
          -  residual volume (RV) ≥ 175% of reference value&#xD;
&#xD;
          -  patient's suitability for endoscopic lung volume reduction according to&#xD;
             multidisciplinary decision of pneumology and thorax surgery division.&#xD;
&#xD;
          -  signed Informed Consent&#xD;
&#xD;
          -  understanding of the nature, significance and implications of the study&#xD;
&#xD;
          -  ability to understand and follow instructions of the study stuff&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  echo-cardiographic right ventricular pressure (PAPsys) &gt; 50 mmHg&#xD;
&#xD;
          -  indication for a permanent anticoagulation therapy (besides ASS)&#xD;
&#xD;
          -  pulmonal cachexia&#xD;
&#xD;
          -  pregnancy and lactating&#xD;
&#xD;
          -  permanent treatment with &gt; 20 mg Prednison per day&#xD;
&#xD;
          -  hospitalisation due to a COPD-exacerbation in the last 3 months&#xD;
&#xD;
          -  &gt; 3 steroid-treated exacerbations in the last year&#xD;
&#xD;
          -  Increase of FEV1 (Forced Expiratory Volume) ≥ 20% after bronchodilatation&#xD;
&#xD;
          -  severe diffusion impairment (DLCO &lt; 20%)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Dreher, Univ.-Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>RWTH University Hospital MK1</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Dreher, Univ.-Prof.</last_name>
    <phone>+49241 80 88763</phone>
    <email>mdreher@ukaachen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tobias Müller, PD Dr.med.</last_name>
    <phone>+49241 80 88763</phone>
    <email>tobmueller@ukaachen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>RWTH Univerity Hospital, Department of Cardiology, Pneumology, Vascular Medicine and Intensive Care Medicine</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Dreher, Univ.-Prof.</last_name>
      <phone>+492418088763</phone>
      <email>mdreher@ukaachen.de</email>
    </contact>
    <contact_backup>
      <last_name>Tobias Müller, PD Dr.med.</last_name>
      <phone>+492418088763</phone>
      <email>tobmueller@ukaachen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>March 20, 2015</study_first_submitted>
  <study_first_submitted_qc>April 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2015</study_first_posted>
  <last_update_submitted>November 18, 2015</last_update_submitted>
  <last_update_submitted_qc>November 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic obstructive pulmonary disease (COPD)</keyword>
  <keyword>endoscopic lung volume reduction</keyword>
  <keyword>Endobronchial valve</keyword>
  <keyword>physical capacity</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

